New Dimension and Landmark Practice Advances in Comprehensive Cardiovascular Protection
Orlando, FL

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This symposium is designed for • cardiologists, non-invasive specialists • Prevention-oriented cardi ologists • Cardiologists, invasive specialists • Cardiovascular nurses • Coronary care unit (CCU) specialists and directors • Specialists in invasive vascular management • Program directors, cardiovascular medicine • Fellows in cardiovascular medicine • Clinical pharmacists and pharmacologists • Pharmacy directors (cardiovascular medicine) • Investigators and clinical trial specialists, invasive cardiology.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to view this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from Novartis Pharmaceuticals.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

Matthew R. Weir, MD
Ad hoc Consultant and Speakers’ Bureau: MSD, Novartis, Boehringer-Ingelheim, Sanofi-Aventis/BMS; Grant/Research: NHLBI and NIDDK

James Ferguson III, MD, FACC
Grant/Research Support: Eisai, The Medicines Company, Viatron/Medtronic
Consultant: BMS, Eisai, Prism, Sanofi-Aventis, Schering Plough, Takeda, The Medicines Company, Therox
Speaker’s Bureau: BMS, Sanofi-Aventis, Schering Plough

Kenneth A. Jamerson, MD
Research Support: NIH, NHLBI, NIH, NIDDK, Novartis, King Pharmaceuticals
Consultant: MSD, Pfizer, Novartis, Speedel

Marc Pfeffer, MD
Honoraria and/or educational or research grants, or serves as a consultant for Astra Zeneca, Aventis, Bristol-Myers Squibb, Merck, Mitsubishi Pharma Corp, Novartis, and Pfizer. The Brigham and Women's Hospital has been awarded a patent regarding the use of inhibitors of the renin-angiotensin system in selected survivors of myocardial infarction. Dr. Pfeffer is among the co-inventors. The licensing agreement with Abbott and Novartis is not linked to sales.

Program Faculty:

Program Chairman
Matthew R. Weir, MD
Professor of Medicine
Division of Nephrology
University of Maryland School of Medicine Baltimore, Maryland

Kenneth A. Jamerson, MD
Professor, Cardiovascular Medicine
University of Michigan Health System
Ann Arbor, Michigan
Past President, International Society on Hypertension in Blacks (ISHIB)

Marc Pfeffer, MD
Professor of Medicine
Harvard Medical School
Cardiovascular Division
Brigham and Women’s Hospital
Boston, Massachusetts

James Ferguson III, MD, FACC
Associate Director, Cardiology Research
Texas Heart Institute at St. Luke’s Episcopal Hospital
Associate Professor
Baylor College of Medicine
Clinical Assistant Professor
University of Texas Health Science Center at Houston
Houston, Texas

Educational Objectives:

Participants in this program will:

• Learn to approach hypertension as a systemic disease, with multiple manifestations, and associations across the cardiovascular morbidity continuum, including metabolic syndrome, HBP, and ischemic heart disease.
• Learn how to evaluate the appropriate role of emerging agents—including direct renin antagonists and combination agents in patients with multiple co-morbid conditions and advanced states of heart disease.
• Learn to clarify their strategy for drug selection of cardiovascular agents, including indi cations for combination therapy: appropriate use strategies for ARBs, ACEIs, diuretics, and/or calcium blockers within the framework of expert-based recommendations.
• Learn how to apply landmark trials to clinical practice to reduce incidence of adverse vascular outcomes in high-risk populations.
• Learn to recognize markers of target organ damage and learn which cardiovascular agents are useful for preventing end organ complications such as ischemic heart dis ease, heart failure, and diabetic renal disease.
• Learn the importance of early treatment of patients with high blood pressure, the clini cal significance of pre-hypertension, and the importance of treating both systolic and diastolic blood pressure abnormalities.
• Learn how to achieve target blood pressure goals as quickly as possible, using combi nation therapy, when indicated.
• Learn to employ therapeutic strategies that reduce side effects and increase the likeli hood of adherence to an antihypertensive drug regimen.
• Learn about the complications linked to healthcare disparities observed in specific patient populations, and customized approaches to these patient subgroups.
• Learn how to manage patients with features of the metabolic syndrome, and its impli cation for multiple risk factor management.
• Learn to clarify their strategy for drug selection of antihypertensive agents, including indications for combination therapy: appropriate use strategies for ARBs, ACEIs, diuret ics, and/or calcium blockers within the framework of expert-based recommendations.
• Learn about the role of emerging therapies, including agents that directly in hibit renin, combination agents using calcium blockers plus ARBs, and cardi oselective selective agents.
• Learn about the role of drugs affecting the RAS on heart failure, high blood pressure, myocardial remodeling, hospitalization rates following MI, cardioprotection, and other CV end points.
• Learn about strategies for reducing hospitalization rates for pa tients with heart failure—role of ARBs, ACEIs, and beta-blockers.
• Learn about strategies for post-myocardial infarction cardio protection, including role of ARBs in patients with left ventricu lar failure and/or dysfunction; role of aspirin; role of statins; role of ACEIs.
• Learn approaches to reducing the risk of developing new-onset dia betes in hypertensive patients at high risk of cardiac events.

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright (c) 2007 All rights reserved